ERBB2 and breast carcinoma: For example, comparison of pre- and post-trastuzumab treatment of tissue samples in metastatic HER2-amplified breast cancer from patients progressing on trastuzumab allowed determination of mutations in PIK3CA and PTEN arising during treatment (4).